Strategic Merger Expansion Stelis Biopharma has recently merged with Steriscience Inc., forming a significant integrated CDMO entity in India with a valuation of Rs. 22,700 crore. This consolidation indicates a growing capacity for large-scale biologic manufacturing, presenting opportunities to offer advanced manufacturing solutions and partnerships to this expanding conglomerate.

Facility Growth and Capacity Despite divesting its Unit 3 facility, Stelis continues to expand its flagship drug substance and drug product operations at the Bangalore site, opening avenues to supply new biologic programs and scale up biologics manufacturing, particularly in cell line development and fill/finish services.

Collaborative Partnerships Recent collaborations with Synoptics Ltd and Syngene demonstrate Stelis’s openness to global partnerships and joint ventures. Companies offering complementary R&D, process development, and scalable manufacturing solutions can leverage this collaborative approach to secure new client relationships.

Strong Investment Backing Having raised $125 million in Series C funding led by TPG Growth, Stelis is well-positioned for further expansion and technology upgrades. Funding opportunities or innovative biotech solutions can align with their growth trajectory and investment interests.

Industry Positioning As a leading biologics CDMO in India with state-of-the-art facilities and strategic location in Bangalore, Stelis offers a competitive advantage for companies seeking reliable manufacturing partners capable of handling complex biologic projects in emerging markets.